Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Cited by (983)

Items 301–400 of 983

1. Chemokine CCL17 Affects Local Immune Infiltration Characteristics and Early Prognosis Value of Lung Adenocarcinoma
   Ting Ye, Bin Zhang, Yongjian Dong, Jing Liu, Wenfeng Zhang, Fenglin Wu, Huaben Bo, Hongwei Shao, Rongxin Zhang, Han Shen · 2022 · Frontiers in Cell and Developmental Biology
2. Association of KDR Mutation With Better Clinical Outcomes in Pan-Cancer for Immune Checkpoint Inhibitors
   Yanan Cui, Pengpeng Zhang, Xiao Liang, Jiali Xu, Xinyin Liu, Yuemin Wu, Junling Zhang, Wei Ting Wang, Fang Zhang, Renhua Guo · 2021 · SSRN Electronic Journal
3. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment
   Neal S. Akhave, Jiexin Zhang, Erin M. Corsini, Meredith L. Frank, Shin‐Heng Chiou, Carmen Behrens, Runzhe Chen, Xin Hu, Edwin Roger Parra, Won‐Chul Lee et al. · 2022 · Lung Cancer
4. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma
   Haibo Zhang, Jian-Yan Pan, Tao Zhu · 2023 · Frontiers in Pharmacology
5. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
   Zhao, Dan, Li, Haiqing, Mambetsariev, Isa, Mirzapoiazova, Tamara, Chen, Chen, Fricke, Jeremy, Kulkarni, Prakash, Villaflor, Victoria, Arvanitis, Leonidas, Hamilton, Stanley et al. · 2022 · Cancers
6. Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
   Nikolaj Frost, Martin Reck · 2024 · American Society of Clinical Oncology Educational Book
7. KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies
   Luigi Liguori, Fabio Salomone, Angela Viggiano, Francesco Sabbatino, Stefano Pepe, Luigi Formisano, Roberto Bianco, Alberto Servetto · 2024 · Critical Reviews in Oncology/Hematology
8. PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer
   Zhengbo Song, Guoping Cheng, Yiping Zhang · 2020 · Journal of Thoracic Disease
9. KALRN mutations promote antitumor immunity and immunotherapy response in cancer
   Mengyuan Li, Yuxiang Ma, You Jia Zhong, Qian Liu, Canping Chen, Lei Qiang, Xiaosheng Wang · 2020 · Journal for ImmunoTherapy of Cancer
10. Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma
    Jin Zhang, Aiting Yan, Wei Cao, Honglei Shi, Kai Cao, Xiaowu Liu · 2020 · Cancer Cell International
11. The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients
    Yan Liu, Hui Li, Jing Zhu, Yang Zhang, Xianhong Liu, Rixin Li, Qiang Zhang, Ying Cheng · 2021 · Cancer Management and Research
12. Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers
    Jiefei Han, Ruofei Yu, Jianchun Duan, Jin Li, Wei Zhao, Guoshuang Feng, Hua Bai, Yuqi Wang, Xue Zhang, Rui Wan et al. · 2021 · Science Advances
13. EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis
    Hui-Min Yang, Jinxiu Zhu, Rendong Xiao, Yuhang Liu, Fanglin Yu, Lin Cai, Minglian Qiu, Fei He · 2021 · Cancer Immunology Immunotherapy
14. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer
    Marina Meri-Abad, Andrea Moreno‐Manuel, Sandra Gallach, Silvia Calabuig Fariñas, Rafael Sirera, Carlos Camps Herrero, Eloisa Jantus Lewintre · 2022 · Critical Reviews in Oncology/Hematology
15. Biomarkers of response to immunotherapy in early stage non-small cell lung cancer
    Matthieu Roulleaux Dugage, Víctor Albarrán-Artahona, Juan Carlos Laguna, Nathalie Chaput, Stéphane Vignot, Benjamin Besse, Laura Mezquita, Édouard Auclin · 2023 · European Journal of Cancer
16. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy
    Francis Proulx-Rocray, Bertrand Routy, Rami Mohamad Nassabein, Wiam Belkaïd, Danh Tran‐Thanh, Julie Malo, Marion Tonneau, Omar El Ouarzadi, Marie Florescu, Mustapha Ali Tehfe et al. · 2023 · Cancer Treatment and Research Communications
17. Toward innovative combinational immunotherapy: A systems biology perspective
    Xuetao Li, Jin‐Ji Yang, Yi-Long Lung Cancer Wu, Jun Hou · 2018 · Cancer Treatment Reviews
18. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
    Roberto Ruiz‐Cordero, Junsheng Ma, Abha Khanna, Genevieve Ray Lyons, Waree Rinsurongkawong, Roland L. Bassett, Ming Guo, Mark J. Routbort, Jianjun J. Zhang, Ferdinandos Skoulidis et al. · 2020 · BMC Cancer
19. Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas
    Sijin Sun, Kailun Fei, Guochao Zhang, Juhong Wang, Yannan Yang, Wei Guo, Zhenlin Yang, Jie Wang, Qi Xue, Yibo Gao et al. · 2021 · Frontiers in Genetics
20. KRAS mutations in endometrial cancers: Possible prognostic and treatment implications
    Karolina A. Kilowski, Martin Frederik Dietrich, Joanne Xiu, Yasmine Baca, Andrew C. Hinton, Sarfraz Ahmad, Thomas J. Herzog, Premal H. Thaker, Robert W. Holloway · 2024 · Gynecologic Oncology
21. Advances in evidence‐based medicine for immunotherapy of non‐small cell lung cancer
    Jingsi Dong, Bingjie Li, Qinghua Zhou, Depei Huang · 2018 · Journal of Evidence-Based Medicine
22. Integrated Genomic Characterization of the Human Immunome in Cancer
    Yongsheng Li, Brandon Burgman, Daniel James McGrail, Ming Sun, Dan Qi, Sachet Ashok Shukla, Erxi Wu, Anna Capasso, Shiaw‐Yih Lin, Catherine J. Wu et al. · 2020 · Cancer Research
23. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma
    Zhiming Chen, Ji Chen, Dandan Ren, Jiao Zhang, Ying Yang, Henghui Zhang, Beibei Mao, Haitao Ma · 2020 · Aging
24. Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer
    Chunxia Su, Xinxin Wang, Juan Zhou, Jing Zhao, Fei Zhou, Guodong Zhao, Xiaohong Xu, Xuan Zou, Bo Zhu, Qingzhu Jia · 2021 · Translational Lung Cancer Research
25. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity
    You Ge, Feiran Wei, Guoping Du, Gaoqiang Fei, Wei Li, Xiaoshan Li, Jinjin Chu, Pingmin Wei · 2021 · BMC Cancer
26. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations
    Jiarong Tan, Chengping Hu, Pengbo Deng, Rongjun Wan, Liming Cao, Min Li, Huaping Yang, Qihua Gu, Jian An, Juan Jiang · 2021 · Frontiers in Oncology
27. PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations
    Tiantian Ma, Jiao Jin, Ran Huo, Xiaofang Li, Guotao Fang, Qi Zhao, Weiwei Liu, Xiao Han, Chenglin Xi, Yanan Wang et al. · 2022 · Frontiers in Oncology
28. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations
    Ruoxue Cai, Hongyu Zhu, Ying L. Liu, Huanhuan Sha, Weiwei Peng, Rong L. Yin, Guoren Zhou, Ying Fang · 2023 · Journal of Cancer Research and Clinical Oncology
29. Intratumoral Heterogeneity in Lung Cancer
    Xiaodi Lv, Zi-Xian Mao, Xian-Jun Sun, Bao-Jun Liu · 2023 · Cancers
30. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma
    Pierre Serra, Arthur Petat, Jean‐Michel Maury, Françoise Thivolet-Béjui, Lara Chalabreysse, Marc Barritault, Nathalie Ebran, Gerard Alain Milano, Nicolas Girard, Marie Brevet · 2018 · Lung Cancer
31. Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features
    Linda Ye, Connull Leslie, Angela Jacques, Nima Mesbah Ardakani, Benhur Amanuel, Michael Millward · 2018 · Modern Pathology
32. Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report
    Cheng Fang, Chu Zhang, Weiqing Zhao, Wenwei Hu, Jun Wu, Mei Ji · 2019 · BMC Medical Genomics
33. Predictive biomarkers for tumor immune checkpoint blockade
    Mengting Tong, Jing Wang, Wenting He, Yanling Wang, Hongming Pan, Da Li, Hongliang Zhang · 2018 · Cancer Management and Research
34. Lamin B1 Overexpresses in Lung Adenocarcinoma and Promotes Proliferation in Lung Cancer Cells via AKT Pathway
    Wei Li, Xiaoqing Li, Xiaoping Li, Mingjiang Li, Pan‐Chyr Yang, Xuhui Wang, Lei Li, Bo Yang · 2020 · OncoTargets and Therapy · Retracted
35. Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
    Noriaki Sunaga, Yosuke Miura, Norimitsu Kasahara, Reiko Sakurai · 2021 · Cancers
36. Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer
    Qiushi Xu, Tong Liu, Junjie Wang · 2022 · Genes
37. Direct GDP-KRAS G12C inhibitors and mechanisms of resistance: the tip of the iceberg
    Joshua C. Rosen, Adrian G. Sacher, Ming‐Sound Tsao · 2023 · Therapeutic Advances in Medical Oncology
38. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway
    Xufen Zheng, Yuxiang Luo, Yangjie Xiong, Xiaoxiao Liu, Chunling Zeng, Xiaojing Lu, Xiaofang Wang, Y. Cheng, Simin Wang, Haoqi Lan et al. · 2023 · Journal for ImmunoTherapy of Cancer
39. Immune checkpoint blockade and biomarkers of clinical response in non–small cell lung cancer
    Andreas Hallqvist, Anna Rohlin, Sukanya Raghavan · 2020 · Scandinavian Journal of Immunology
40. Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer
    Bassel Alsaed, Nina Bobik, Hanna K. Laitinen, Tanvi Nandikonda, Ilkka Ilonen, Heidi M. Haikala · 2025 · Cancer and Metastasis Reviews
41. Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma
    Qiyun Ou, Yunfang Yu, Anlin Li, Jie Chen, Tingting Yu, Xiaolin Xu, Xinxin Xie, Yongjian Chen, Dagui Lin, Qiaohong Zeng et al. · 2020 · Annals of Translational Medicine
42. Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients
    Peng Song, Dongliang Yang, Hanping Wang, Xiaoxia Cui, Xiaoyan Si, Xiaotong Zhang, Li Zhang · 2020 · Thoracic Cancer
43. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab
    Haiyong Wang, Qinge Shan, Jun Guo, Xiao Han, Chenglong Zhao, Huijuan Li, Zhehai Wang · 2020 · Lung Cancer
44. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer
    Guangsheng Zhu, Dian Ren, Lei Xi, Ruifeng Shi, Shuai Zhu, Ning Zhou, Lingling Zu, Ramon Andrade de Mello, Jun Chen, Song Xu · 2021 · Cancers
45. Updates in the molecular pathology of non-small cell lung cancer
    Elizabeth C. Paver, Sandra A O'Toole, Xin Min Cheng, Annabelle M. Mahar, Wendy A. Cooper · 2021 · Seminars in Diagnostic Pathology
46. The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study
    Sissel Gyrid Freim Wahl, Hong Yan Dai, Elisabeth Fritzke Emdal, Thomas Berg, Tarje Onsøien Halvorsen, Anine Larsen Ottestad, Marius Lund‐Iversen, Odd Terje Brustugun, Dagny Førde, Erna‐Elise Paulsen et al. · 2021 · Cancers
47. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer
    Chen Chen, Tao Wang, Mengmei Yang, Jia Tao Song, Mengli Huang, Yuezong Bai, Hao Su · 2021 · Pathology & Oncology Research
48. Myosteatosis can Predict Unfavorable Outcomes in Advanced Hepatocellular Carcinoma Patients Treated With Hepatic Artery Infusion Chemotherapy and Anti-PD-1 Immunotherapy
    Xiaoping Yi, Yan Hong Huang Fu, Qianyan Long, Yazhuo Zhao, Sai Li, Chunhui Zhou, Huashan Lin, Xiaolian Liu, Chang Liu, Changyong Chen et al. · 2022 · Frontiers in Oncology
49. TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy
    Jiangyong Yu, Zaiwen Fan, Zhipeng Zhou, Ping Zhang, Jing Bai, Xu Li, Min Tang, Nannan Fan, Xiaonan Wu, Xin Nie et al. · 2022 · Cancers
50. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)
    Yanjun Wang, Shuo Yang, Li Wan, Wei Ling, Hao Hui Chen, Jinghua Wang · 2023 · International Journal of Oncology
51. Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers
    Joan Miguel Romero, Emma Titmuss, Yifan Wang, James Vafiadis, Alain Pacis, Gun Ho Jang, Amy Xin Wei Zhang, Bryn Golesworthy, Tatiana Lenko, Laura Williamson et al. · 2023 · npj Precision Oncology
52. Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma
    Juan Feng, Yang Lan, Feng Liu, Ye Yuan, Jia Ge, Sen Wei, Hu Luo, Jianjun Li, Tao Luo, Xiu‐Wu Bian · 2023 · npj Precision Oncology
53. Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
    Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote, Maria Zurera Berjaga, Jorge Esteban-Villarrubia, Jon Zugazagoitia Fraile, Luis G Paz-Ares · 2024 · Drugs
54. Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation
    Shifeng Yang, Xinmin Yu, Yun Fan, Xun Shi, Ying Jin · 2018 · Journal of Cancer
55. EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis
    Yue Zhao, Yunjian Pan, Chao Cheng, Difan Zheng, Yang Zhang, Zhendong Gao, Fangqiu Fu, Hang Li, Shanbo Zheng, Lingdun Zhuge et al. · 2020 · Journal of Cancer Research and Clinical Oncology
56. Amplifying Tumor–Stroma Communication: An Emerging Oncogenic Function of Mutant p53
    Valeria Capaci, Fiamma Mantovani, Giannino Del Sal · 2021 · Frontiers in Oncology
57. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors
    Song Li, Jing Gao, Qian Xu, Xue Zhang, Miao Huang, Xin Dai, Kai Huang, Lian Liu · 2021 · Frontiers in Immunology
58. TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
    Ruofei Yu, Hua Bai, Tangai Li, Bingyu Gao, Jiefei Han, Geyun Chang, Pei Zhang, Kailun Fei, Xiran He, Jie Wang · 2021 · Translational Oncology
59. Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
    Bin Qiu, Kaican Cai, Chun Chen, Jun Chen, Ke‐Neng Chen, Qixun Chen, Chao Cheng, Tianyang Dai, Junqiang Fan, Zhaohui Fan et al. · 2021 · Translational Lung Cancer Research
60. Aligning digital CD8+ scoring and targeted next‐generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early‐stage squamous cell lung carcinoma
    Esther Conde, Alejandra Caminoa, Carolina Domínguez, Antonio Calles, Stefan Walter, Bárbara Angulo, Elena Sánchez, Marta Alonso, Luis Jimenez, Luis Íñigo Madrigal et al. · 2017 · Histopathology
61. Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
    Angela Listì, Nadia Barraco, Marco Bono, Lavinia Insalaco, Luisa Castellana, Sofia Cutaia, Maria Rita Ricciardi, Valerio Gristina, Enrico Bronte, Gianni Pantuso et al. · 2018 · Translational Cancer Research
62. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis
    Guihua Zhang, Rong Dong, Demiao Kong, Bo Liu, Yan Zha, Meng Luo · 2021 · Anti-Cancer Agents in Medicinal Chemistry
63. Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
    Junjie Teng, Kai Zhou, Dongxiao Lv, Changshun Wu, Hong Feng · 2022 · Frontiers in Pharmacology
64. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy
    Fengying Wu, Tao Jiang, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi et al. · 2022 · 癌症：英文版
65. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
    Jie Peng, Jing Zhang, Dan Zou, Lushan Xiao, Honglian Ma, Xudong Zhang, Ya Li, Lijie Han, Baowen Xie · 2022 · Frontiers in Immunology
66. Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations
    Yuxi Liu, Alexander Gusev, Peter L. Kraft · 2023 · Cancer Research
67. Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
    Man Wang, Lijie Zhu, Xiaoxu Yang, Jiahui Li, Yue Liu, Tang Ying · 2023 · Frontiers in Pharmacology
68. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis
    Bin Jiang, Liwen Hu, Daling Dong, Zixin Guo, Wei Wei, Chao Wang, Weikang Shao, Ting Ma, Yanhui Chen, Qingyun Li et al. · 2023 · Journal of Cancer Research and Clinical Oncology
69. MDM2 inhibitors in cancer immunotherapy: Current status and perspective
    Qinru Zeng, Shaocheng Zeng, Xiaofeng Dai, Yun Ding, Chunye Huang, Ruiwen Ruan, Jianping Xiong, Xiaomei Tang, Jun Deng · 2024 · Genes & Diseases
70. CSF1R and HCST: Novel Candidate Biomarkers Predicting the Response to Immunotherapy in Non-Small Cell Lung Cancer
    Xiaoguang Qi, Chunyan Qi, Tao Wu, Yi Hu · 2020 · Technology in Cancer Research & Treatment
71. Role of p53-miRNAs circuitry in immune surveillance and cancer development: A potential avenue for therapeutic intervention
    Deepti Singh, Mohammad Afsar Khan, Hifzur Rahman Siddique · 2021 · Seminars in Cell and Developmental Biology
72. Efficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations
    Alexander P. Davis, Wendy A. Cooper, Michael Joseph Boyer, Jenny Lee, Nick Pavlakis, Steven Kao · 2021 · Immunotherapy
73. Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Hyojin Kim, Hyun Jung Kwon, Eun Sun Kim, Soohyeon Kwon, Kyoung Jin Suh, Se Hyun Kim, Yu Jung Kim, Jong Seok Lee, Jin-Haeng Chung · 2021 · Cancer Research and Treatment
74. Artificial intelligence–enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation
    Xiaodong Wang, Di Xiong, Songli Cui, Bingchen Duan, Gouping Ding, Yiping Huang, Qianqian Wang · 2026 · Frontiers in Immunology
75. The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients
    Ying Yang, Shengping Shen, Yingjia Sun, Hatim Husain, Haiyan Zhou, Shun Lü, Ziming Li · 2022 · Translational Lung Cancer Research
76. A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer
    Jie Peng, Lushan Xiao, Dan Zou, Lijie Han · 2022 · Frontiers in Medicine
77. Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics
    Yang Yang, Yajuan Qu, Zhaopeng Li, Zhiyong Tan, Youming Lei, Song Bai · 2022 · Frontiers in Genetics
78. Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates
    Attila A. Seyhan, Claudio Carini · 2022 · International Journal of Molecular Sciences
79. Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
    Lixiu Peng, Jun Guo, Li Kong, Yong Huang, Ning Tang, Juguang Zhang, Minglei Wang, Xiaohan He, Zhenzhen Li, Yonggang Peng et al. · 2023 · Frontiers in Oncology
80. From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy
    Seyed Esmaeil Ahmadi, Elahe Rahimian, Samira Rahimi, Bahman Zarandi, Mehran Bahraini, Maral Soleymani, Seyed Mehrab Safdari, Ashkan Shabannezhad, Niloofar Jaafari, Majid Safa · 2024 · Biomarker Research
81. Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
    Ke Ma, Qingqing Jin, Miao Wang, Xin Li, Yuyang Zhang · 2019 · Expert Review of Molecular Diagnostics
82. Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development
    Leandro Jonata de Carvalho Oliveira, Aline Bobato Lara Gongora, Denis L. Fontes Jardim · 2020 · Current Oncology Reports
83. Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma
    Masayuki Shirasawa, Tatsuya Yoshida, Daisuke Takayanagi, Kouya Shiraishi, Shigehiro Yagishita, Katsutoshi Sekine, Shintaro Kanda, Yuji Matsumoto, Ken Masuda, Yuki Shinno et al. · 2021 · Clinical Lung Cancer
84. Identification and Validation of Efficacy of Immunological Therapy for Lung Cancer From Histopathological Images Based on Deep Learning
    Yachao Yang, Jialiang Yang, Yuebin Liang, Bo Liao, Wen Zhu, Xiaofei Mo, Kaimei Huang · 2021 · Frontiers in Genetics
85. Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma
    Mingyu Zhu, Haiyan Cui, Lu Zhang, Kuo Zhao, Xiaochen Jia, Hao Jin · 2021 · Translational Cancer Research
86. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma
    Yao Liang, Osamu Maeda, Chiaki Kondo, Kazuki Nishida, Yuichi Ando · 2024 · PLoS ONE
87. Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review
    Fan Zhang, Banglu Wang, Menghuan Wu, Liwen Zhang, Mei Qing Ji · 2025 · Frontiers in Immunology
88. KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape
    Austin Frisch, Eric Martin, So Yeon Kim, Jonathan Wesley Riess, Triparna Sen, Nagla Abdel Karim · 2025 · The Oncologist
89. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery
    Eric de Sousa, Joana R. Lérias, Antonio Lopez-beltran B, Georgia Paraschoudi, Carolina Condeço, Jéssica Kamiki, Patrícia António, Nuno Figueiredo, Carlos Torres Carvalho, Mireia Castillo-Martín et al. · 2021 · Frontiers in Immunology
90. A Prognostic Gene Signature for Hepatocellular Carcinoma
    Rong Chen, Meng Zhao, Yanli An, Dongfang Liu, Qiusha Tang, Gao‐Jun Teng · 2022 · Frontiers in Oncology
91. Identification of Hub Genes Associated With the Development of Stomach Adenocarcinoma by Integrated Bioinformatics Analysis
    Kehui Zhang, Jian Wang, Yingying Zhu, Xiaolin Liu, Jiacheng Li, Zhe Shi, Mengxing Cao, Yong Li · 2022 · Frontiers in Oncology
92. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China
    Qianni Li, Qi Zhou, Shicai Zhao, Peng Wu, Ping Shi, Jia Zeng, Xiaomin Xiong, Haiwen Chen, Muaiad Kittaneh, Sara Bravaccini et al. · 2022 · Translational Lung Cancer Research
93. The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
    Rui Zhao, Shu Yang, Wei Xu, Fengxian Jiang, Pancen Ran, Liying Pan, Jingliang Wang, Weihao Wang, Jing Zhao, Yahui Wang et al. · 2024 · Cancer Cell International
94. Biomarkers of immunotherapy in non-small cell lung cancer
    Ling-Ling Wang, Yue Hu, Shengchao Wang, Jiali Shen, Xiao-Chen Wang · 2020 · Oncology Letters
95. Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer
    Yang Zheng, Lili Tang, Ziling Liu · 2021 · BMC Cancer
96. HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer
    Wenjing Zhang, Zhijuan Lin, Fuyan Shi, Qiang Wang, Yujia Kong, Yanfeng Ren, Juncheng Lyu, Chao Sheng, Yuting Li, Hao Qin et al. · 2022 · Cancers
97. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
    Yiming Ma, Jun Yang, Tiantai Ji, Fengyun Wen · 2022 · Frontiers in Genetics
98. TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations
    Armin Frille, Myriam Boeschen, Hubert R. W. Wirtz, Mathias Stiller, Hendrik Bläker, Maximilian von Laffert · 2024 · Frontiers in Oncology
99. A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma
    William Zhao, Thinh T. Nguyen, Atharva Bhagwat, Akhil Kumar, Bruno Giotti, Benjamin Kepecs, Jason L. Weirather, Navin R. Mahadevan, Åsa Segerstolpe, Komal Dolasia et al. · 2025 · Nature Cancer
100. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
     Xilin Hu, Hanlin Xu, Qianwen Xue, Ruran Wen, Wenjie Jiao, Kaihua Tian · 2021 · Molecular Medicine